Advertisement
BAX vs RMD
Which Stock Would AI Choose? Baxter International (BAX) vs. ResMed (RMD) Stock Comparison
Key Takeaways
- BAX and RMD both operate in the medtech sector, with BAX offering a broader portfolio across infusion systems, renal care, and pharmaceuticals while RMD focuses primarily on sleep apnea and respiratory solutions.
- Year-to-date through late July 2026, both stocks have outperformed the broader market, with BAX returning approximately 17% and RMD approximately 18%.
- BAX reported first-quarter 2026 results with modest reported sales growth and reiterated its full-year outlook amid upcoming second-quarter earnings expected on July 30.
- RMD delivered strong third-quarter fiscal 2026 results with 11% revenue growth and margin expansion, though shares have faced sector-related pressure tied to potential impacts from GLP-1 weight-loss medications.
- Market capitalizations stand at roughly $11.6 billion for BAX versus approximately $28.3 billion for RMD, reflecting differences in scale and growth profiles.
- Relative performance in recent weeks has shown resilience for both, influenced by earnings visibility and broader healthcare sector dynamics.
Introduction
Investors and traders often compare BAX and RMD to assess relative value within the medical technology space. Both companies serve critical healthcare needs yet differ in product focus, growth trajectories, and market positioning. This comparison appeals to those evaluating healthcare exposure, particularly individuals or institutions seeking to balance defensive characteristics with growth potential in a sector sensitive to regulatory, reimbursement, and innovation cycles. The analysis highlights observable factors such as recent earnings trends, valuation context, and sector influences to support informed decision-making without forward-looking predictions.
BAX Overview and Recent Performance
Baxter International develops and markets a diversified range of medical products, including infusion pumps, intravenous solutions, renal dialysis equipment, and select pharmaceuticals. In recent market activity, the stock has traded around the $22 level, supported by year-to-date gains that have exceeded the S&P 500 benchmark. First-quarter 2026 results showed reported sales of $2.7 billion, reflecting a 3% increase on a reported basis, though organic sales declined modestly. Management reiterated its full-year 2026 guidance of flat to 1% reported sales growth. Upcoming second-quarter earnings, scheduled for July 30, carry expectations of year-over-year declines in both revenue and earnings per share amid ongoing operational and cost pressures. Sentiment in recent weeks has reflected cautious optimism tied to earnings visibility and broader medtech demand stability.
RMD Overview and Recent Performance
ResMed specializes in devices and software for sleep-disordered breathing, including continuous positive airway pressure (CPAP) systems and related respiratory care solutions. The stock has recently traded near $195, posting year-to-date returns that have also surpassed the broader market. Third-quarter fiscal 2026 results, reported in late April, featured revenue of $1.4 billion, up 11% on a reported basis and 8% constant currency, alongside non-GAAP earnings per share of $2.86 and notable gross margin expansion. The company maintains a solid cash generation profile. Shares have encountered some downward pressure in recent periods amid sector-wide healthcare concerns, including potential competitive or demand shifts related to GLP-1 medications. Fourth-quarter fiscal 2026 earnings are anticipated on August 6, providing further insight into demand trends.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of high-performing AI trading bots from a much larger library of hundreds available across the platform. These bots trade thousands of different tickers using varied strategies, timeframes, and risk parameters. Only those demonstrating the strongest alignment with prevailing market conditions—based on metrics such as consistency, drawdown control, and adaptability—earn placement in the trending section. Performance statistics among available bots can range widely depending on style and timeframe, offering users diverse options for different market environments. All bots maintain distinct profiles in terms of win rates, profit factors, and ticker coverage. Review the Trending AI Robots page to explore current selections.
Head-to-Head Comparison
BAX maintains a wider product portfolio spanning multiple therapeutic areas, which can provide revenue diversification but also exposes it to varied reimbursement and competitive pressures. In contrast, RMD operates with a more concentrated focus on sleep and respiratory care, potentially enabling stronger margin leverage during periods of sustained demand. Recent momentum has favored both through outperformance versus the market, though RMD has delivered more robust top-line growth in its latest reported quarter compared with BAX’s modest organic results. Risk factors differ: BAX faces manufacturing and cost headwinds ahead of earnings, while RMD navigates narrative concerns around long-term market expansion. Sector exposure overlaps in healthcare but diverges in end-market sensitivity, with BAX showing greater breadth and RMD higher concentration. Market sentiment reflects balanced interest tempered by upcoming catalysts for each name.
Tickeron AI Verdict
Based on observable factors such as recent earnings consistency, revenue growth rates, and relative positioning within the medtech sector, Tickeron’s AI would currently assign a higher probabilistic preference to RMD. Stronger top-line expansion and margin trends in the most recent quarter provide a more stable trend signal compared with the more mixed organic performance and near-term earnings caution surrounding BAX. This assessment remains probabilistic and tied to current data patterns rather than guarantees of future results.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BAX is a Hold and RMD is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BAX’s FA Score shows that 2 FA rating(s) are green whileRMD’s FA Score has 1 green FA rating(s).
- BAX’s FA Score: 2 green, 3 red.
- RMD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BAX’s TA Score shows that 5 TA indicator(s) are bullish while RMD’s TA Score has 5 bullish TA indicator(s).
- BAX’s TA Score: 5 bullish, 4 bearish.
- RMD’s TA Score: 5 bullish, 5 bearish.
Price Growth
BAX (@Pharmaceuticals: Other) experienced а -2.98% price change this week, while RMD (@Pharmaceuticals: Other) price change was +5.91% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.26%. For the same industry, the average monthly price growth was +8.63%, and the average quarterly price growth was +6.97%.
Reported Earning Dates
BAX is expected to report earnings on Oct 29, 2026.
RMD is expected to report earnings on Oct 22, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+3.26% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| BAX | RMD | BAX / RMD | |
| Capitalization | 13.8B | 32.4B | 43% |
| EBITDA | 762M | 2.18B | 35% |
| Gain YTD | 40.016 | -6.319 | -633% |
| P/E Ratio | 87.85 | 21.52 | 408% |
| Revenue | 11.5B | 5.54B | 208% |
| Total Cash | 2.15B | 1.66B | 129% |
| Total Debt | 9.67B | 843M | 1,147% |
BAX | RMD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 84 | 29 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 39 | |
PRICE GROWTH RATING 1..100 | 5 | 49 | |
P/E GROWTH RATING 1..100 | 33 | 81 | |
SEASONALITY SCORE 1..100 | 50 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RMD's Valuation (13) in the Medical Specialties industry is significantly better than the same rating for BAX (92). This means that RMD’s stock grew significantly faster than BAX’s over the last 12 months.
RMD's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BAX (100). This means that RMD’s stock grew similarly to BAX’s over the last 12 months.
RMD's SMR Rating (39) in the Medical Specialties industry is somewhat better than the same rating for BAX (96). This means that RMD’s stock grew somewhat faster than BAX’s over the last 12 months.
BAX's Price Growth Rating (5) in the Medical Specialties industry is somewhat better than the same rating for RMD (49). This means that BAX’s stock grew somewhat faster than RMD’s over the last 12 months.
BAX's P/E Growth Rating (33) in the Medical Specialties industry is somewhat better than the same rating for RMD (81). This means that BAX’s stock grew somewhat faster than RMD’s over the last 12 months.
| BAX | RMD | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 58% | 1 day ago 68% |
| Stochastic ODDS (%) | 1 day ago 60% | 1 day ago 69% |
| Momentum ODDS (%) | 1 day ago 67% | 1 day ago 56% |
| MACD ODDS (%) | 1 day ago 74% | 1 day ago 66% |
| TrendWeek ODDS (%) | 1 day ago 66% | 1 day ago 57% |
| TrendMonth ODDS (%) | 1 day ago 64% | 1 day ago 58% |
| Advances ODDS (%) | 11 days ago 57% | 2 days ago 56% |
| Declines ODDS (%) | 3 days ago 65% | 8 days ago 60% |
| BollingerBands ODDS (%) | 1 day ago 52% | 1 day ago 71% |
| Aroon ODDS (%) | 1 day ago 70% | 1 day ago 60% |
Advertisement
RMD and
Correlation & Price change
A.I.dvisor indicates that over the last year, RMD has been loosely correlated with COO. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if RMD jumps, then COO could also see price increases.
| Ticker / NAME | Correlation To RMD | 1D Price Change % | ||
|---|---|---|---|---|
| RMD | 100% | -1.01% | ||
| COO - RMD | 50% Loosely correlated | -0.56% | ||
| BAX - RMD | 47% Loosely correlated | -1.18% | ||
| SOLV - RMD | 46% Loosely correlated | +2.46% | ||
| BDX - RMD | 46% Loosely correlated | +0.79% | ||
| ISRG - RMD | 43% Loosely correlated | -1.68% | ||
More | ||||